Source: Annual Congress 2005 - New perspectives in asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. A. Lewis, L. Jordan, D. C. Farr, J. Fozard (Horsham, United Kingdom; Basel, Switzerland). Indacaterol: preclinical evidence for an improved safety profile vs LABAs. Eur Respir J 2005; 26: Suppl. 49, 1401

Member's Comments

No comment yet.

Related content which might interest you: Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials Source: Eur Respir J 2009; 33: 21-32 Year: 2009 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 Efficacy and safety of transdermal tulobuterol (LABA) on asthma patients Source: Annual Congress 2007 - New treatments for asthma Year: 2007 Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses Source: International Congress 2019 – Therapeutic breakthrough Year in review Year: 2019 Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial Source: Eur Respir J 2003; 22: 787-794 Year: 2003 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 AMPLIFY: efficacy of aclidinium vs tiotropium in COPD Source: International Congress 2018 – COPD management Year: 2018 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019